Abstract
Coagulation factors, 11-dehydro-TxB2 (metabolite of TxA2) and 6-keto-PGF1 alpha (metabolite of PGI2) levels in 87 women who were treated for 9 months with oral contraceptives (OC) containing low doses of oestrogens and progestogens (Triquilar, Trinovum or Cilest) were investigated. In plasma, increases in F I, II, VII, VIII-c and 11-dehydro-TxB2 levels, but no modification of 6-keto-PGF1 alpha were observed. In urine, FPA concentration rose, but no change occurred in 11-dehydro-TxB2 and 6-keto-PGF1 alpha levels. No marked difference between the 3 OC preparations were noted. These data, and particularly the large increase of 11-dehydro-TxB2 (p < 0.01) suggest that a hypercoagulable state persists in low dosage OC users.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
MeSH terms
-
6-Ketoprostaglandin F1 alpha / blood
-
Adult
-
Analysis of Variance
-
Contraceptives, Oral / pharmacology*
-
Ethinyl Estradiol / pharmacology
-
Factor VII / analysis
-
Factor VIII / analysis
-
Female
-
Fibrinogen / analysis
-
Humans
-
Levonorgestrel / pharmacology
-
Norethindrone / pharmacology
-
Norgestrel / analogs & derivatives
-
Norgestrel / pharmacology
-
Prothrombin / analysis
-
Thromboxane B2 / analogs & derivatives*
-
Thromboxane B2 / blood
Substances
-
Contraceptives, Oral
-
Norgestrel
-
Ethinyl Estradiol
-
Thromboxane B2
-
6-Ketoprostaglandin F1 alpha
-
Levonorgestrel
-
11-dehydro-thromboxane B2
-
Factor VII
-
Prothrombin
-
Factor VIII
-
Fibrinogen
-
norgestimate
-
Norethindrone